Management of retinoblastoma: are we there yet?

Vishal Raval, Arun Singh

Journal: Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 2024;59(6):376-379

PMID: 38431272

Full Text on Elsevier Science View on PubMed

Abstract

Since the introduction of intraarterial chemotherapy (IAC) in the last decade, there has been a paradigm shift in the management of retinoblastoma (RB), especially in developed countries. Despite improved globe salvage outcomes with IAC compared with systemic intravenous chemotherapy, IAC has certain limitations, such as poor accessibility and affordability, especially for middle- and low-income countries; the need for expertise; local ocular complications; and possible increased risk of systemic metastasis. This review discusses the important limitations of the current treatment strategy of using IAC, as well as the prospects of new therapeutic targets or routes of drug delivery that may lead to further improvements in the management of RB.

Address: The Operation Eyesight Universal Institute for Eye Cancer, L V Prasad Eye Institute, Hyderabad, India.; Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio.. Electronic address: [email protected].

DOI: 10.1016/j.jcjo.2024.01.013

Link outs

Subscription / membership required

Full Text Sources:

MeSH Terms: Retinoblastoma, Humans, Retinal Neoplasms, Infusions, Intra-Arterial, Antineoplastic Agents